Navigation Links
Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections
Date:9/14/2009

thousands of laser drilled holes. Compared to other nebulization technologies, eFlow Technology produces aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible period of time. Combined with its silent mode of operation, small size (it fits in the palm of the hand), light weight, and battery use, products incorporating eFlow Technology reduce the burden of taking daily, inhaled treatments. The eFlow Nebulizer System and eFlow Technology are proprietary to PARI Pharma and can be optimized to specific drug formulations.

About Transave, Inc.

Transave, Inc., is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of chronic lung diseases. The company's major focus is on developing antibiotic therapy delivered via proprietary advanced pulmonary liposome technology in areas of high unmet need in lung diseases. The Transave team is dedicated to leveraging its development and commercialization expertise, along with its intellectual property, to bring life-extending and life-enhancing medicines to patients. For more information about Transave's technology and development programs, visit http://www.transaveinc.com/.


'/>"/>
SOURCE Transave, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
2. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
3. Tobira Therapeutics Inc. Announces In Vitro Data of TBR-652 for the Treatment of HIV
4. Exsulin Corporation Announces Next Phase II Trial of Novel Islet Regeneration Treatment in Type 1 Diabetes
5. ISTA Pharmaceuticals Announces Preliminary Results of T-Pred Studies
6. BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury
7. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
8. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
9. Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
10. Vion Pharmaceuticals Announces Results of the Oncologic Drugs Advisory Committee Meeting for Onrigin(TM)
11. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... -- Indianapolis interventional medical device maker NICO Corporation ... visualization leader Synaptive Medical announced today ... that they have joined forces to integrate their ... the first of its kind and will make ... BrainPath® interventional access technology and Synaptive,s BrightMatter™ real-time ...
(Date:10/20/2014)... 20, 2014 Valeritas, Inc., a leader in ... with Type 2 diabetes, announced today that it has ... The award was presented October 16 th at ... Ohio . The Cardinal Health ... variety of metrics specifically targeted at the importance of ...
(Date:10/20/2014)... N.J. , Oct. 20, 2014   ... Pharmaceutical Co., Ltd. ( Japan ), ... (FDA) granted Fast Track designation for TAS-102 (nonproprietary ... anticancer drug under investigation for the treatment of ... Company has initiated a rolling NDA submission to ...
Breaking Medicine Technology:Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
... Blood Test for DepressionSAN DIEGO, April 23 ... commercializing its first-in-class, proprietary blood test for depression ... Phase 2, National Science Foundation, Small Business Innovation ... be used to further the clinical development and ...
... review of several vendors, the University of California ... services of Velos and its flagship product, Velos eResearch. ... UCLA,s Jonsson Comprehensive Cancer Center and an affiliated clinical ... in place to deploy the system in non-cancer studies ...
Cached Medicine Technology:Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant 2University of California Los Angeles Selects Velos eResearch 2University of California Los Angeles Selects Velos eResearch 3University of California Los Angeles Selects Velos eResearch 4University of California Los Angeles Selects Velos eResearch 5University of California Los Angeles Selects Velos eResearch 6
(Date:10/22/2014)... (PRWEB) October 22, 2014 The ... , which is dedicated to distribute health information ... healthcare delivery worldwide announced the development of six ... patients expect when receiving healthcare. These are an ... patient-centered care: “providing care that is respectful of ...
(Date:10/22/2014)... October 22, 2014 Healthcare professionals ... their continuing education at home or on-the-go via ... to 20 brand new, premium Seminar-on-Demand CE courses. ... of over 2,000 hours of CE ... their educational experience. With such a diverse library, ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately held ... infections, microbial biofilms, and chronic wounds, announced that Dr. ... , Dr. Sinskey is a Professor ... of Technology, or MIT. He has been a member ... holds positions as Co-Director of the Malaysia-MIT Biotechnology Partnership ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... crucial part of conventional in vitro fertilization (IVF) -- the ... take place in a device inside the vagina, new research ... that the device, called an INVOcell, might sharply cut costs ... make the technology more accessible to those who don,t live ...
(Date:10/20/2014)... October 20, 2014 With a mere ... Charlie Crist made a brief fundraising stop at the ... Thursday. , Fresh from a debate last night with ... the stage for the first seven minutes because Crist ... governor described the incident in one word: "weird." , ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3
... LOS ANGELES, Sept. 12 The Lupus Foundation,of America ... Jada Smith,Family Foundation is set to host the first ... at the historic El Rey Theatre in,Los Angeles on ... and funds for lupus. Butterflies Over Hollywood will ...
... TORONTO, Sept. 12 /PRNewswire-FirstCall/ - Transition Therapeutics ... a product-focused,biopharmaceutical company developing therapeutics for disease ... results for the year,ended June 30, 2007. ... fiscal 2007 and up to the date ...
... VivoMetrics(R) Inc. and the,Philadelphia Flyers of the ... incorporated the VivoChampionTrainer System into the team,s,training regimen ... use of,the VivoChampionTrainer as pre-season Training Camp kicked ... will be utilizing the VivoChampionTrainer to optimize their,players, ...
... Team Facilities Treated with the Antimicrobial Protection of the ... SportsAide(R) System from SportCoatings(TM), ... Nets are,the next team in the NBA scoring with ... from antimicrobial contamination. SportsAide is part of the ...
... Sept. 12 Children with asthma across the,country are ... annual "Living with Asthma" poster contest sponsored by the ... American Academy of,Pediatrics (AAP). More than 9 million children ... for them to understand that asthma shouldn,t,keep them from ...
... Meeting Expectations today announced,that it has been named ... the industry,s,largest and most influential full-service independent meeting ... market. Compiled by,Penton Media,s Corporate Meetings & Incentives(R) ... corporate meetings and events,industry, the CMI 25 provides ...
Cached Medicine News:Health News:The Will and Jada Smith Family Foundation and Maybelline Join Forces With the Lupus Foundation of America for a Star-studded Gala to Raise Awareness for Lupus 2Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 2Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 3Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 4Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 5Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 6Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 7Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 8Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 9Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 10Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 11Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 12Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 13Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 14Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 15Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 16Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 17Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 18Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 19Health News:Philadelphia Flyers to Use VivoChampionTrainer(TM) System to Condition and Strengthen Players 2Health News:Philadelphia Flyers to Use VivoChampionTrainer(TM) System to Condition and Strengthen Players 3Health News:New Jersey Nets Shoot Down Staph with High-Tech Defense 2Health News:Kids, How Do You Manage Your Asthma? The AAAAI and AAP announce 17th annual poster contest 2Health News:Meeting Expectations Named to First Annual 'CMI 25' List by Corporate Meetings & Incentives Magazine 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: